BRIOChe: Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma
Trial summary:
BRIOChe aims to compare radiotherapy re-irradiation with chemotherapy in patients with recurrent glioblastoma (GBM). The trial will assess 9 month overall survival as well as quality of life. 70 patients will be recruited from UK sites over 2 years.
RT QA summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire |  | |
| Outlining Benchmark Case | | 1 case | |
| Planning Benchmark Case | | 1 case | |
| Dummy Run | |||
| During Accrual | Individual Case Review | | Prospective: first patient and first patient where PTV is in close proximity to OAR PRV |
| Data collection | | All patients | |
| Dosimetry | | ||
| QA Streamlining | | Applies to outlining only: CamBMT, HIPPO, ROAM, PARADIGM, PARADIGM2 |
RTTQA contact: BRIOCheqa.enh-tr@nhs.net
Chief investigator: Dr Louise Murray, St James’s University Hospital Leeds
Sponsor: University of Leeds BRIOCHE@leeds.ac.uk (CTRU Brioche)
Funder: Jon Moulton Charity Trust